Study promising: Joint venture to target dry AMD treatment


St. Louis, MO-TLC Vision Corp. has made an equity investment in Vascular Sciences Corp. to establish OccuLogix, a 50/50 joint venture to commercialize Vascular Sciences' Rheopheresis blood filtration process for treating age-related macular degeneration (AMD).

Recent Videos
© 2024 MJH Life Sciences

All rights reserved.